183 related articles for article (PubMed ID: 29337963)
1. Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2.
Bahleda R; Varga A; Bergé Y; Soria JC; Schnell D; Tschoepe I; Uttenreuther-Fischer M; Delord JP
Br J Cancer; 2018 Feb; 118(3):344-352. PubMed ID: 29337963
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
Suder A; Ang JE; Kyle F; Harris D; Rudman S; Kristeleit R; Solca F; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J; Spicer J
Eur J Cancer; 2015 Nov; 51(16):2275-84. PubMed ID: 26296295
[TBL] [Abstract][Full Text] [Related]
3. A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours.
Gazzah A; Boni V; Soria JC; Calles A; Even C; Doger B; Mahjoubi L; Bahleda R; Ould-Kaci M; Esler A; Nazabadioko S; Calvo E
Eur J Cancer; 2018 Nov; 104():1-8. PubMed ID: 30278378
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.
Mukai H; Masuda N; Ishiguro H; Mitsuma A; Shibata T; Yamamura J; Toi M; Watabe A; Sarashina A; Uttenreuther-Fischer M; Ando Y
Cancer Chemother Pharmacol; 2015 Oct; 76(4):739-50. PubMed ID: 26254023
[TBL] [Abstract][Full Text] [Related]
5. Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors.
Hiret S; Isambert N; Gomez-Roca C; Bennouna J; Sassi M; de Mont-Serrat H; Fan J; Schnell D; Delord JP
Invest New Drugs; 2018 Dec; 36(6):1044-1059. PubMed ID: 29808308
[TBL] [Abstract][Full Text] [Related]
6. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H
Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours.
Bahleda R; Hollebecque A; Varga A; Gazzah A; Massard C; Deutsch E; Amellal N; Farace F; Ould-Kaci M; Roux F; Marzin K; Soria JC
Br J Cancer; 2015 Nov; 113(10):1413-20. PubMed ID: 26512876
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of volasertib combined with afatinib, in advanced solid tumors.
Machiels JP; Peeters M; Herremans C; Surmont V; Specenier P; De Smet M; Pilz K; Strelkowa N; Liu D; Rottey S
Cancer Chemother Pharmacol; 2015 Oct; 76(4):843-51. PubMed ID: 26349473
[TBL] [Abstract][Full Text] [Related]
9. A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors.
O'Brien MER; Sarker D; Bhosle J; Thillai K; Yap TA; Uttenreuther-Fischer M; Pemberton K; Jin X; Wiebe S; de Bono J; Spicer J
Cancer Chemother Pharmacol; 2018 Nov; 82(5):757-766. PubMed ID: 30088048
[TBL] [Abstract][Full Text] [Related]
10. A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
Moran T; Palmero R; Provencio M; Insa A; Majem M; Reguart N; Bosch-Barrera J; Isla D; Costa EC; Lee C; Puig M; Kraemer S; Schnell D; Rosell R
Lung Cancer; 2017 Jun; 108():154-160. PubMed ID: 28625629
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer.
Martin N; Isambert N; Gomez-Roca C; Goeldner RG; Zanetta S; Sadrolhefazi B; de Mont-Serrat H; Campone M; Delord JP
Cancer Chemother Pharmacol; 2018 Dec; 82(6):979-986. PubMed ID: 30350178
[TBL] [Abstract][Full Text] [Related]
12. Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine.
Goh G; Schmid R; Guiver K; Arpornwirat W; Chitapanarux I; Ganju V; Im SA; Kim SB; Dechaphunkul A; Maneechavakajorn J; Spector N; Yau T; Afrit M; Ahmed SB; Johnston SR; Gibson N; Uttenreuther-Fischer M; Herrero J; Swanton C
PLoS Med; 2016 Dec; 13(12):e1002136. PubMed ID: 27923043
[TBL] [Abstract][Full Text] [Related]
13. Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer.
Marshall J; Shapiro GI; Uttenreuther-Fischer M; Ould-Kaci M; Stopfer P; Gordon MS
Future Oncol; 2013 Feb; 9(2):271-81. PubMed ID: 23414476
[TBL] [Abstract][Full Text] [Related]
14. A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors.
Chu QS; Sangha R; Hotte SJ; Sergenson G; Schnell D; Chand VK; Hirte HW
Invest New Drugs; 2014 Dec; 32(6):1226-35. PubMed ID: 25037863
[TBL] [Abstract][Full Text] [Related]
15. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
Farhat F; Kattan JG; Ghosn M
Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
[TBL] [Abstract][Full Text] [Related]
16. Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial.
Hickish T; Mehta A; Liu MC; Huang CS; Arora RS; Chang YC; Yang Y; Vladimirov V; Jain M; Tsang J; Pemberton K; Sadrolhefazi B; Jin X; Tseng LM
Breast Cancer Res Treat; 2022 Apr; 192(3):593-602. PubMed ID: 35138529
[TBL] [Abstract][Full Text] [Related]
17. Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer.
Ring A; Wheatley D; Hatcher H; Laing R; Plummer R; Uttenreuther-Fischer M; Temple G; Pelling K; Schnell D
Clin Cancer Res; 2015 Jun; 21(12):2737-44. PubMed ID: 25370464
[TBL] [Abstract][Full Text] [Related]
18. A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors.
Vermorken JB; Rottey S; Ehrnrooth E; Pelling K; Lahogue A; Wind S; Machiels JP
Ann Oncol; 2013 May; 24(5):1392-400. PubMed ID: 23293114
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors.
Spicer J; Irshad S; Ang JE; Enting D; Kristeleit R; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J
Cancer Chemother Pharmacol; 2017 Jan; 79(1):17-27. PubMed ID: 27872953
[TBL] [Abstract][Full Text] [Related]
20. A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors.
Gordon MS; Springett GM; Su YB; Ould-Kaci M; Wind S; Zhao Y; LoRusso PM
Future Oncol; 2015; 11(10):1479-91. PubMed ID: 25963426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
